Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer.

Conversely, a positive trend was observed between MCS categories and the risk of death, with HR increasing from 1.36 (1.17 to 1.59) to 1.88 (1.48 to 2.39) in patients with MCS between 10 and 19 and in those with MCS greater than 30, respectively, as compared to those with MCS less than 10 ( Table 2 ). 2.2.

also in 11,005 other papers